Literature DB >> 2413157

Acquisition of cytotoxic T lymphocyte-specific carbohydrate differentiation antigens.

L Lefrancois, L Puddington, C E Machamer, M J Bevan.   

Abstract

Cytotoxic T cell (CTL)-specific activation antigens, termed CT determinants, have been detected by monoclonal antibodies (mAb) that inhibit CTL function. At the cell surface, the CT antigens are associated with the T200 glycoproteins and two other proteins of Mr 140,000 and 85,000 and are present on a secreted protein, gp155. Periodate treatment followed by binding analysis and immunoprecipitation experiments using tunicamycin-treated cells indicated that carbohydrate is necessary for CT antigen expression. Furthermore, gp155 is secreted in the presence of tunicamycin while retaining the CT antigens, and the CT determinants are added late in T200 biosynthesis, suggesting that the CT glycans are O-linked. Finally, interleukin 2 was shown to dramatically influence the expression of the CT mAb-reactive oligosaccharides present at the CTL cell surface.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413157      PMCID: PMC2187862          DOI: 10.1084/jem.162.4.1275

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  60 in total

1.  Generation of cytolytic T lymphocytes in vitro. IX. induction of secondary CTL responses in primary long-term MLC by supernatants from secondary MLC.

Authors:  J E Ryser; J C Cerottini; K T Brunner
Journal:  J Immunol       Date:  1978-02       Impact factor: 5.422

2.  A procedure for removing red cells and dead cells from lymphoid cell suspensions.

Authors:  W F Davidson; C R Parish
Journal:  J Immunol Methods       Date:  1975-06       Impact factor: 2.303

3.  Peptide mapping by limited proteolysis in sodium dodecyl sulfate and analysis by gel electrophoresis.

Authors:  D W Cleveland; S G Fischer; M W Kirschner; U K Laemmli
Journal:  J Biol Chem       Date:  1977-02-10       Impact factor: 5.157

4.  Differences in the surface proteins of mouse B and T cells.

Authors:  I S Trowbridge; P Ralph; M J Bevan
Journal:  Proc Natl Acad Sci U S A       Date:  1975-01       Impact factor: 11.205

5.  Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera.

Authors:  E Nakayama; H Shiku; E Stockert; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

6.  Properties and applications of monoclonal antibodies directed against determinants of the Thy-1 locus.

Authors:  A Marshak-Rothstein; P Fink; T Gridley; D H Raulet; M J Bevan; M L Gefter
Journal:  J Immunol       Date:  1979-06       Impact factor: 5.422

7.  Interspecies spleen-myeloma hybrid producing monoclonal antibodies against mouse lymphocyte surface glycoprotein, T200.

Authors:  I S Trowbridge
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

8.  Cell surface glycoproteins of murine cytotoxic T lymphocytes. I. T 145, a new cell surface glycoprotein selectively expressed on Ly 1-2+ cytotoxic T lymphocytes.

Authors:  A K Kimura; H Wigzell
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

9.  Mouse alloantibodies capable of blocking cytotoxic T-cell function. I. Relationship between the antigen reactive with blocking antibodies and the Lyt-2 locus.

Authors:  N Shinohara; D H Sachs
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

10.  Selective affinity fractionation of murine cytotoxic T lymphocytes (CTL). Unique lectin specific binding of the CTL associated surface glycoprotein, T 145.

Authors:  A Kimura; H Wigzell; G Holmquist; B Ersson; P Carlsson
Journal:  J Exp Med       Date:  1979-02-01       Impact factor: 14.307

View more
  14 in total

1.  Parallel pattern of expression of CD43 and of LFA-1 on the CD45RA+ (naive) and CD45RO+ (memory) subsets of human CD4+ and CD8+ cells. Correlation with the aggregative response of the cells to CD43 monoclonal antibodies.

Authors:  R Youseffi-Etemad; B Axelsson
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

2.  CD45 expression by murine B cells and T cells: alteration of CD45 isoforms in subpopulations of activated B cells.

Authors:  K S Hathcock; H Hirano; R J Hodes
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Expression of UDP-N-acetylgalactosamine: beta-galactose beta 1,4-N-acetylgalactosaminyltransferase in functionally defined T-cell clones.

Authors:  A Conzelmann; C Bron
Journal:  Biochem J       Date:  1987-03-15       Impact factor: 3.857

4.  Altered patterns of glycosylation on rat lymphocytes associated with activation.

Authors:  P Sutton; R W Stoddart; I V Hutchinson
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

5.  Structural features of Ly-5 glycoproteins of the mouse and counterparts in other mammals.

Authors:  J S Tung; Y Saga; E A Boyse
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

6.  B-cell variant of mouse T200 (Ly-5): evidence for alternative mRNA splicing.

Authors:  M L Thomas; P J Reynolds; A Chain; Y Ben-Neriah; I S Trowbridge
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

7.  Organization of the Ly-5 gene.

Authors:  Y Saga; J S Tung; F W Shen; T C Pancoast; E A Boyse
Journal:  Mol Cell Biol       Date:  1988-11       Impact factor: 4.272

8.  The monoclonal antibody, UCHL1, recognizes a 180,000 MW component of the human leucocyte-common antigen, CD45.

Authors:  L A Terry; M H Brown; P C Beverley
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

9.  Structural variants of human T200 glycoprotein (leukocyte-common antigen).

Authors:  S J Ralph; M L Thomas; C C Morton; I S Trowbridge
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

10.  Lymphocyte specific heterogeneity in the rat leucocyte common antigen (T200) is due to differences in polypeptide sequences near the NH2-terminus.

Authors:  A N Barclay; D I Jackson; A C Willis; A F Williams
Journal:  EMBO J       Date:  1987-05       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.